BACKGROUND: Hereditary motor and sensory neuropathy type Ia (HMSN Ia) is known as a primarily demyelinating peripheral nerve disease. Evidence is accumulating that axonal involvement determines the course of the disease process. METHODS: Fifty-one patients were investigated. Physical disability and impairments were scored. Nerve conduction velocities (NCVs) were used as indirect measures for myelination status and compound muscle/sensory nerve action potential (CMAP/SNAP) amplitudes served as indirect measures for axonal function. RESULTS: Median age was 39 years (range 6-69). Muscle weakness and sensory dysfunction was more severe in the legs than in the arms and distally more than proximally. However, more than 40% of the patients had proximal muscle weakness in the legs. Three point grip was used as representative of combined distal arm muscle groups. CMAP amplitude was the most important independent variable in a multiple linear regression model (forward selection) to explain the relation between three point grip strength and four different features, i. e., CMAP amplitude of the abductor pollicis brevis, median nerve MNCV, gender, and duration of signs and symptoms. The severity of axonal dysfunction was nerve length-dependent and was related to the myelination status. The mild physical disability due to both muscle weakness and sensory dysfunction was also related to axonal dysfunction. CONCLUSIONS: In HMSN Ia, clinical disease severity at the impairment and disability levels is related to the severity of axonal dysfunction. Our data support the hypothesis that the myelination status is one of the factors that determine the extent of axonal dysfunction later in life. Proximal weakness of the legs is encountered in a considerable proportion of our patients.
BACKGROUND:Hereditary motor and sensory neuropathy type Ia (HMSN Ia) is known as a primarily demyelinating peripheral nerve disease. Evidence is accumulating that axonal involvement determines the course of the disease process. METHODS: Fifty-one patients were investigated. Physical disability and impairments were scored. Nerve conduction velocities (NCVs) were used as indirect measures for myelination status and compound muscle/sensory nerve action potential (CMAP/SNAP) amplitudes served as indirect measures for axonal function. RESULTS: Median age was 39 years (range 6-69). Muscle weakness and sensory dysfunction was more severe in the legs than in the arms and distally more than proximally. However, more than 40% of the patients had proximal muscle weakness in the legs. Three point grip was used as representative of combined distal arm muscle groups. CMAP amplitude was the most important independent variable in a multiple linear regression model (forward selection) to explain the relation between three point grip strength and four different features, i. e., CMAP amplitude of the abductor pollicis brevis, median nerve MNCV, gender, and duration of signs and symptoms. The severity of axonal dysfunction was nerve length-dependent and was related to the myelination status. The mild physical disability due to both muscle weakness and sensory dysfunction was also related to axonal dysfunction. CONCLUSIONS: In HMSN Ia, clinical disease severity at the impairment and disability levels is related to the severity of axonal dysfunction. Our data support the hypothesis that the myelination status is one of the factors that determine the extent of axonal dysfunction later in life. Proximal weakness of the legs is encountered in a considerable proportion of our patients.
Authors: M F Ritz; J Lechner-Scott; R J Scott; P Fuhr; N Malik; B Erne; V Taylor; U Suter; N Schaeren-Wiemers; A J Steck Journal: J Neuroimmunol Date: 2000-05-01 Impact factor: 3.478
Authors: A A Gabreëls-Festen; E M Joosten; F J Gabreëls; F G Jennekens; T W Janssen-van Kempen Journal: J Neurol Sci Date: 1992-02 Impact factor: 3.181
Authors: P K Thomas; W Marques; M B Davis; M G Sweeney; R H King; J L Bradley; J R Muddle; J Tyson; S Malcolm; A E Harding Journal: Brain Date: 1997-03 Impact factor: 13.501
Authors: K M Krajewski; R A Lewis; D R Fuerst; C Turansky; S R Hinderer; J Garbern; J Kamholz; M E Shy Journal: Brain Date: 2000-07 Impact factor: 13.501
Authors: Ingemar S J Merkies; Paul I M Schmitz; Frans G A Van Der Meché; Johnny P A Samijn; Pieter A Van Doorn Journal: Muscle Nerve Date: 2002-03 Impact factor: 3.217
Authors: Henriette M E Bienfait; Camiel Verhamme; Ivo N van Schaik; Johannes H T M Koelman; Bram W Ongerboer de Visser; Rob J de Haan; Frank Baas; Baziel G M van Engelen; Marianne de Visser Journal: J Neurol Date: 2006-08-28 Impact factor: 4.849
Authors: José Berciano; Elena Gallardo; Antonio García; Ana L Pelayo-Negro; Jon Infante; Onofre Combarros Journal: J Neurol Date: 2011-05-18 Impact factor: 4.849
Authors: Luuk Wieske; Camiel Verhamme; Esther Witteveen; Aline Bouwes; Daniela S Dettling-Ihnenfeldt; Marike van der Schaaf; Marcus J Schultz; Ivo N van Schaik; Janneke Horn Journal: Neurocrit Care Date: 2015-06 Impact factor: 3.210
Authors: Ana L Pelayo-Negro; Elena Gallardo; Antonio García; Pascual Sánchez-Juan; Jon Infante; José Berciano Journal: J Neurol Date: 2014-01-22 Impact factor: 4.849
Authors: Mônica de Carvalho Alcântara; Marcello H Nogueira-Barbosa; Regina Maria França Fernandes; Geruza Alves da Silva; Charles Marques Lourenço; Heide H Sander; Wilson Marques Junior Journal: J Neurol Date: 2015-03-13 Impact factor: 4.849
Authors: Camiel Verhamme; Rob J de Haan; Marinus Vermeulen; Frank Baas; Marianne de Visser; Ivo N van Schaik Journal: BMC Med Date: 2009-11-12 Impact factor: 8.775
Authors: Sinéad M Murphy; David N Herrmann; Michael P McDermott; Steven S Scherer; Michael E Shy; Mary M Reilly; Davide Pareyson Journal: J Peripher Nerv Syst Date: 2011-09 Impact factor: 3.494